Biotech Stocks Hit 52-Week Highs on Trial Data, Offerings

Several biotech stocks reached 52-week highs on September 18, 2026, lifted by clinical trial results and announced public offerings. HeartSciences (HSCS) rose 7%, while FRNM gained 5%. VOGX, HTFL and HALO also touched 52-week highs during the session. The moves reflect continued investor appetite for sector catalysts, with trial readouts and equity raises driving individual names higher rather than a broad sector rally. Specific financial terms of the offerings and trial data were not disclosed in the initial reports.